

Supplementary Table 1. Quantification of VEGF in ascites, pleural effusions, plasma, and serum of cancer patients

Ref	Year	Cancer ¹	VEGF isoform ²	Method ³	Statistics ⁴	n	Diagnosis ⁵	VEGF source ⁶	[VEGF] (mean/median)	Std. Dev.	unit	[VEGF] (pM)	[VEGF] (pg/ml)
<i>Specific cancers</i>													
<u>Kraft et al., 1999</u> [†]	1999	BC	NS	ELISA	MCI; R	12	all pat.	PE	885		pg/ml	20	885
						129	Met, Nmet	Serum	362		pg/ml	8	362
Zebrowski et al., 1999	1999	BC	NS	ELISA	MR	7	all pat.	PE	47		pg/mg protein	31	1410
Sun et al., 2003	2003	CRC	NS	ELISA	MSE	5	all pat.	Ascites	403	140	pg/ml	9	403
Sun et al., 2003	2003	GC	NS	ELISA	MSE	6	all pat.	Ascites	541	123	pg/ml	12	541
<u>Kraft et al., 1999</u>	1999	GIC	NS	ELISA	MCI; R	9	all pat.	PE	813		pg/ml	18	813
						48	Met, Nmet	Serum	433		pg/ml	10	433
Jin et al., 2004	2004	LC	NS	ELISA	MSE	40	all pat.	PE	2596	719	pg/ml	58	2596
<u>Kishiro et al., 2002</u>	2002	LC	121, 165, 189	ELISA	MSE	5	all pat.	PE	17526	22498	pg/ml	389	17526
						28	S. (IIIA-IV)	Plasma	161	177	pg/ml	4	161
<u>Matsuyama et al., 2000</u>	2000	LC	121, 165	ELISA	MSE	6	S. (I-IV)	PE	532	285	pg/ml	12	532
						49	S. (I-IV)	Serum	406		pg/ml	9	406
<u>Sack et al., 2005</u>	2005	LC	NS	ELISA	MSE	58	all pat.	PE	2349 ^e	2910	pg/ml	52	2349
						58	all pat.	Serum	500	140	pg/ml	11	500
Thickett et al., 1999	1999	LC	NS	ELISA	MR	36	all pat.	PE	2500		pg/ml	56	2500
Yanagawa et al., 1999	1999	LC	NS	EIA	MSE	60	all pat.	PE	2920	820	pg/ml	65	2920
Zebrowski et al., 1999	1999	LC	NS	ELISA	MR	15		PE	75		pg/mg protein	50	2250
Zhou et al., 2009	2009	LC	NS	ELISA	MSE	62	all pat.	PE	3710	1650	pg/ml	82	3710
Zebrowski et al., 1999	1999	Lym	NS	ELISA	MR	6	all pat.	PE	31		pg/mg protein	21	930
Zebrowski et al., 1999	1999	Mes	NS	ELISA	MR	4	all pat.	PE	145		pg/mg protein	97	4350
<u>Harlozinska et al., 2004</u>	2004	OC	165	ELISA	MR	52	S. (I-IV)	Ascites	3035		pg/ml	67	3035
						86	S. (I-IV)	Serum	389		pg/ml	9	389
<u>Kraft et al., 1999</u>	1999	OC	NS	ELISA	MCI; R	28	all pat.	PE	5528		pg/ml	123	5528
						35	Met, Nmet	Serum	1022		pg/ml	23	1022
Nascimento et al., 2004	2004	OC	NS	ELISA	Md	13	all pat.	Ascites	1266		pg/ml	28	1266
<u>Rudlowski et al., 2006</u>	2006	OC	NS	ELISA	MR	65	S. (I-IV)	Ascites	2575		pg/ml	57	2575
						65	S. (I-IV)	Serum	174		pg/ml	4	174

Ref	Year	Cancer ¹	VEGF isoform ²	Method ³	Statistics ⁴	n	Diagnosis ⁵	VEGF source ⁶	[VEGF] (mean/median)	Std. Dev.	unit	[VEGF] (pM)	[VEGF] (pg/ml)
Sun et al., 2003	2003	OC	NS	ELISA	MSE	8	all pat.	Ascites	866	208	pg/ml	19	866
Yabushita et al., 2003	2003	OC	NS	EIA	MSE	24	S. (I-IV)	Ascites	1465	238	pg/ml	33	1465
<u>Yamamoto et al., 1997</u>	1997	OC	NS	SEI	MSE	12	S. (I-IV)	Ascites	2971	4025	pg/ml	66	2971
						21	S. (I-IV)	Serum	295	237	pg/ml	7	295
Zebrowski et al., 1999	1999	RCC	NS	ELISA	MR	3	all pat.	PE	82		pg/mg protein	55	2460
Zebrowski et al., 1999	1999	Sarcoma	NS	ELISA	MR	4	all pat.	PE	32		pg/mg protein	21	960
<i>Multiple cancer types</i>													
Duysinx et al., 2008	2008	BC, Lar, LC, Gen, KC, OC, PC, Sk, M	NS	ELISA	MR	64	all pat.	PE	665		pg/ml	15	665
<u>Economidou et al., 2008</u>	2008	LC, U met	NS	ELISA	MR	22	all pat.	PE	657		pg/ml	15	657
						22	all pat.	Serum	571		pg/ml	13	571
Gieseler et al., 2007	2007	GIC, LC, OC	NS	ELISA	MES	60	all pat.	PE	1286	66	pg/ml	29	1286
<u>Hamed et al., 2004</u>	2004	LC, BC, Lym	NS	ELISA	MSE	15	all pat.	PE	1007	445	pg/ml	22	1007
						15	all pat.	Serum	814	291	pg/ml	18	814
<u>Ishimoto et al., 2002</u>	2002	LC, Lym, Mes, Pan	NS	ELISA	MR	32	all pat.	PE	1350		pg/ml	30	1350
						32	all pat.		381		pg/ml	8	381
<u>Kyotza et al., 2010</u>	2010	BC, GIC, LC, OC, others	NS	xMAP	MR	116	all pat.	PE	170		pg/ml	4	170
						116	all pat.	Serum	30		pg/ml	1	30
Lee et al., 2008	2008	CRC, Eso, GB, OC, Klastkin tumor, Pan, Stom, U met	NS	ELISA	MSE	21	S. (IV)	Ascites	349	491	pg/ml	8	349
Nascimento et al., 2004	2004	BC, CRC, End, GC, L, Pan, PC, U	NS	ELISA	Md	19	all pat.	Ascites	672		pg/ml	15	672
Richardson et al., 2002	2002	GC, L met, OC	NS	ELISA	MSE	6	all pat.	Ascites	4800	1700	pg/ml	107	4800
<u>Shu et al., 2007</u>	2007	*	NS	EIA	MSE	32	all pat.	PE	1358	1493	pg/ml	30	1358
						32	all pat.	Serum	650	533	pg/ml	14	650
Verheul et al., 2000	2000	BC, GIC, LC, M, Mes, OC, STS, U	NS	ELISA	MR	47	all pat.	Ascites or PE	1290		pg/ml	29	1290
Xue et al., 2007	2007	BC, LC, Lym, Mes	NS	ELISA	MSE	42	all pat.	PE	1135	321	pg/ml	25	1135

Footnotes

- 1 BC - Breast Cancer, CRC - Colorectal Cancer, End - Endometrial Cancer, Eso - Esophageal Cancer, GB, Glioblastoma, GC - Gastric Cancer, Gen - Genital, GIC - Gastrointest Cancer, L - Liver, Lar - Laryngeal Cancer, LC - Lung Cancer, Lym. - Lymphoma, KC - Kidney, OC - Ovarian Cancer, M - Melanoma, Mes - Mesothelioma, Pan - Pancreatic Car PC - Prostate Cancer, RCC - Renal Cell Carcinoma, Sk - Skin, Stom - Stomach, STS - Soft Tissue Sarcoma, U - Unknown; met - Metastases present
- 2 NS - Not specified
- 3 ELISA - Enzyme-Linked Immunosorbent Assay, EIA - Enzyme Immuno Assay, SEI - Sandwich Enzyme Immunoassay
- 4 Me - Mean, Md - Median, MR - Median and Range, MSE - Mean and Standard Error, R - Range, SD - Standard Deviation
- 5 all pat. - All Patients, Met. - Metastatic Cancer; Nmet - Nonmetastatic Cancer; S. (I-IV) - UICC Stage
- 6 PE - Pleural effusion
- e Estimate based on reported subgroup data
- * primary bronchogenic carcinomas, adenocarcinomas of unknown origin, cancerous cells of indefinite origins discovered in PF, breast carcinoma, non-Hodgkin's lymphoma, squamous carcinoma of unknown origin
- † Underlined references report VEGF levels in ascites/PE and blood (plasma or serum)